APA (7th ed.) Citation

Liu, Q., Guan, Y., & Li, S. (2024). Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: The "all-around warrior" in immunotherapy. Molecular Cancer, 23(1), 1. https://doi.org/10.1186/s12943-024-02095-8

Chicago Style (17th ed.) Citation

Liu, Qiang, Yujing Guan, and Shenglong Li. "Programmed Death Receptor (PD-)1/PD-ligand (L)1 in Urological Cancers: The "All-around Warrior" in Immunotherapy." Molecular Cancer 23, no. 1 (2024): 1. https://doi.org/10.1186/s12943-024-02095-8.

MLA (9th ed.) Citation

Liu, Qiang, et al. "Programmed Death Receptor (PD-)1/PD-ligand (L)1 in Urological Cancers: The "All-around Warrior" in Immunotherapy." Molecular Cancer, vol. 23, no. 1, 2024, p. 1, https://doi.org/10.1186/s12943-024-02095-8.